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Abstract
Background: Aim of this longitudinal study was to investigate the sensitivity to change of the Swedish
Self Evaluation of Communication Experiences after Laryngeal Cancer questionnaire (the S-SECEL),
addressing communication dysfunction in patients treated for laryngeal cancer. Previous studies have
highlighted the need for more specific questionnaires for this purpose.
Methods: 100 patients with Tis-T4 laryngeal cancer were included prior to treatment onset. Patients
answered four questionnaires at six occasions during one year; the S-SECEL, the European Organisation
for Research and Treatment of Cancer (EORTC) Core Quality of Life Core Questionnaire (QLQ-C30)
supplemented by the Head and Neck cancer module (QLQ-H&N35) and the Hospital Anxiety and
Depression (HAD) scale. In addition, performance status was assessed. Differences within groups were
tested with the Wilcoxon paired signed ranks test and between-group analyses were carried out using the
Mann-Whitney U test. Magnitude of group differences was analyzed by means of effect sizes.
Results: The S-SECEL was well accepted with a response rate of 76%. Communication dysfunction
increased at 1 month, followed by a continuous decrease throughout the year. Changes were statistically
significant at most measurement, demonstrating the sensitivity of the S-SECEL to changes in
communication over time. The S-SECEL and the EORTC QLQ-C30 with the QLQ-H&N35 demonstrated
similar results; however the S-SECEL was more sensitive regarding communication dysfunction. The
largest changes were found in the most diagnose specific items concerning voice and speech.
Conclusion: The S-SECEL was investigated in the largest Scandinavian longitudinal study concerning
health-related quality of life (HRQL) in laryngeal cancer patients. The questionnaire was responsive to
change and showed convergent results when compared to established HRQL questionnaires. Our findings
also indicate that the S-SECEL could be a more suitable instrument than the EORTC QLQ-C30 with QLQ-
H&N35 when measuring communication experiences in patients with laryngeal cancer; it is more sensitive,
shorter and can be used on an individual basis. As a routine screening instrument the S-SECEL could be a
valuable tool for identifying patients at risk for psychosocial problems and to help plan rehabilitation. It is
therefore recommended for clinical use in evaluation of communication dysfunction for all patients with
laryngeal cancer irrespective of treatment.
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Background
Patients with head and neck cancer not only have to deal
with the impact of a life-threatening disease, but also with
the effect of treatment on physical, psychological, and
social functioning. Studies have indicated that as many as
one third of cancer patients suffer from psychiatric mor-
bidity [1-3]. Regarding head and neck cancer the last dec-
ade has seen a growing interest regarding the health-
related quality of life (HRQL) for these patients, and func-
tional status have been recognized as important outcome
variables in the evaluation of head and neck cancer treat-
ment [4-6]. A number of reliable and valid HRQL ques-
tionnaires have been developed, e.g. the Functional
Assessment of Cancer Therapy-General and the Head &
Neck module (FACT-G & FACT-H&N) [7], the Perform-
ance Status Scale for Head and Neck Cancer Patients (PSS-
HN) [8,9], the EORTC Core Quality of Life Questionnaire
and the Head & Neck module (EORTC QLQ-C30 &
EORTC QLQ-H&N35) [10,11], and these questionnaires
have resulted in a better understanding of the impact of
treatment in head and neck oncology. However, they
include only few questions addressing voice and commu-
nication dysfunction, issues of particular importance to
laryngeal cancer patients [12,13].
Therefore, a short but comprehensive self-report instru-
ment measuring perceived adjustment to communication
experiences in laryngeal cancer patients treated with laryn-
gectomy, the Self Evaluation of Communication Experi-
ences after Laryngectomy (SECEL), was developed and
psychometrically evaluated in the United States [14]. The
SECEL has been used as a screening tool to develop rec-
ommendations for intensive counselling, and for evaluat-
ing the effects of voice therapy and rehabilitation on the
patients' daily living activities. For identifying the patients
in need of further rehabilitation and in-depth counselling,
the original authors have recommended a specific cut off
value. [14,15]. The SECEL has been adapted to Swedish
conditions and revised for use in laryngeal cancer patients
receiving different treatment modalities [16]. The results
lent support to the S-SECEL as a potentially useful out-
come measure in patients with laryngeal cancer. It was
also tested for sensitivity of change on a small group of
patients (n = 26), where results after one year demon-
strated a decrease in communication dysfunction [17].
The primary aim of the present study investigated whether
the S-SECEL was sensitive to changes in communication
and psychosocial dysfunction over time in a large cohort
of laryngeal cancer patients. Secondary aim was to evalu-
ate longitudinal score changes in relation to established
and validated HRQL instruments.
Methods
Patients
All patients with newly diagnosed or relapsing laryngeal
cancer in the western part of Sweden are continuously
admitted to a weekly tumour conference at Sahlgrenska
University Hospital, where the appropriate cancer treat-
ment for each patient is discussed. During the inclusion
period, all patients with laryngeal cancer were asked to
participate in the current study were excluded from the
study, as well as patients with some other concurrent can-
cer diagnosis and patients participating in other studies.
During the study period 210 patients with laryngeal can-
cer were admitted to the tumour conference, 100 were
included in the study while 110 patients were excluded.
Reasons for exclusion were poor general health (WHO
performance status 3–4) or dementia diagnosed by a psy-
chiatrist or GP (56), participation in other studies (19),
poor knowledge of Swedish (10), family reasons (3),
other concurrent cancer disease (3), and unknown rea-
sons (2). Another 17 patients declined participation.
Design
Data used in this prospective longitudinal study was
derived from a battery of Patient Related Outcome (PRO)
questionnaires. The study was ongoing between 1998 and
2005 with a discontinuation for two years. Results from
repeated measures were compared for three forms; the S-
SECEL, the HAD scale and the EORTC QLQ-C30 with
QLQ-H&N35.
Participants answered questionnaires regarding HRQL
and voice and speech on six occasions during a follow-up
time of one year. Before start of treatment (baseline) ques-
tionnaires were distributed to patients at the tumour con-
ference and mailed-back. A mail-out/mail-back procedure
was used for follow-up assessments at 1, 2, 3, 6 and 12
months after start of treatment. Patients who had not
returned their questionnaires within 2–3 weeks were
reminded once by mail. Patients were further followed up
with a visit to the outpatient clinic 12 months after treat-
ment start, with recording of received treatment and eval-
uation of performance status and residual tumour.
At the conference, diagnosis according to TNM (UICC)
and ICD and histopathology was recorded. Performance
status was rated according to the WHO performance scale.
For clinical purposes, the patients were asked about previ-
ous and present diseases, present symptoms, weight loss
and smoking habits. Socio-demographic data such as fam-
ily situation, education level, occupation, and smoking
habits were also recorded.BMC Cancer 2008, 8:80 http://www.biomedcentral.com/1471-2407/8/80
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Treatment
All patients had received or were receiving radiotherapy as
part of their treatment. The majority of the patients with
T0-T1 disease received conventionally fractionated radia-
tion therapy, a few received hyper fractionated radiation
therapy. Patients with T2-T4 disease received either hyper
fractionated radiotherapy or conventionally fractionated,
in a majority the regional nodes were also irradiated as
well. Chemotherapy was given to 9 patients with stage III-
IV tumours. One patient was laryngectomised before
inclusion in the study, 2 patients were treated with pri-
mary laryngectomy and 4 patients were treated with laryn-
gectomy as salvage surgery during the study year.
Questionnaires
S-SECEL
The original Self Evaluation of Communication Experi-
ences after Laryngectomy (SECEL) was developed to
assess communication dysfunction in patients with laryn-
gectomies and has demonstrated satisfactory psychomet-
ric properties [14]. The Swedish version (S-SECEL, App)
was adapted for use in patients who receive different treat-
ments for laryngeal cancer. Two items in the original
SECEL, specifically addressing experiences after laryngec-
tomy, were re-worded in the S-SECEL. Otherwise the S-
SECEL is congruent with the original SECEL in both its
format and content. The S-SECEL has proved reliable and
shown both convergent and discriminant validity and sat-
isfactory internal consistency [16,17].
The questionnaire consists of 35 items addressing com-
munication experiences and dysfunction (App I). 34 of
the items are aggregated into three subscales. The first sub-
scale, General (5 items), describes general attitudes about
being relaxed or calm and acknowledgement of the sick-
ness and treatment. Examples of questions are "Do you
think that your speech improves with practice?" or
"Would you describe yourself as outgoing and talkative?"
The second subscale, Environmental (14 items), focuses
on how the patient experiences his/her voice in different
environments. Questions are for example; "Do you have
trouble speaking in a large room?" and "Do you have dif-
ficulty yelling or calling out to people?" The third sub-
scale, Attitudinal (15 items), describes attitudes about
speech, feelings about self-perceptions and perceptions of
others, for example "Do you avoid speaking because of
your voice?" and "Do you feel that people get annoyed
with you because of your voice?" Each item is rated on a
4-point categorical scale ranging from 0 (never) to 3
(always), and addressing the last 30 days. Scoring of sub-
scales and a total scale is carried out by simple addition.
Thus, the summary scale scores range from 0–15 for Gen-
eral, 0–42 for Environmental, 0–45 for Attitudinal and
0–102 for Total, respectively. A higher score indicates
greater perceived communication dysfunction. The 35th
item "Do you talk the same amount now as before your
laryngeal cancer" has three response categories, Yes/More/
Less, and is not included in the scoring system.
EORTC QLQ-C30 and QLQ-H&N35
The EORTC Study Group on Quality of Life has developed
a modular measurement system for evaluating quality of
life in cancer patients participating in clinical trials [18]. A
30-item core questionnaire, the EORTC QLQ-C30,
assesses the physical and psychosocial functioning and
symptom experiences of cancer patients in general [10].
To address additional symptoms associated specifically
with head and neck cancer and its treatment, a comple-
mentary 35-item module can be used, the QLQ-H&N35
[19,20]. When tested in large, cross-cultural samples of
patients with cancer, both the core questionnaire [10] and
the head and neck cancer-specific module [20] have dem-
onstrated satisfactory to excellent reliability and validity.
Of particular importance is the ability of these question-
naires to distinguish between patient groups differing in
clinical status and to detect changes in patients' clinical
status over time.
Calculated scale scores range from 0–100. On the Func-
tioning scales and Global quality of life scale a score of
100 corresponds to maximum functioning, whereas on
the Symptom scales and items a score of 100 means worst
possible symptoms [21]. A change in score over time of >
10 points should be interpreted as clinically significant
[22].
Hospital Anxiety and Depression (HAD) scale
The HAD scale is a tool detecting mood disorders in
somatically ill patients [23] and has frequently been used
in cancer studies, for example lung cancer [24] and head
and neck cancer [25,26]. The 2-factor structure has been
confirmed in many studies [27,28]. The Swedish version
has been documented in several studies [29]. HAD con-
sists of 14 items on a four-point response scale ranging
from 0–3. The summary scale scores for anxiety (7 items)
and depression (7 items) thus range from 0–21. Each per-
son is also grouped according to a clinically tested classi-
fication of psychiatric morbidity. A scale score < 8 is in the
normal range, a score 8–10 indicates a possible and a
score > 10 indicates a probable mood disorder.
Statistical methods
The statistical software SPSS 14.0 for Windows was used
in the statistical analyses.
Descriptive statistics with 95% confidence interval (CI)
were calculated according to standard procedures. Differ-
ences within groups were tested with the Wilcoxon paired
signed ranks test and between-group analyses were carried
out using the Mann-Whitney U test. Level of significanceBMC Cancer 2008, 8:80 http://www.biomedcentral.com/1471-2407/8/80
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was set at 5% throughout. Clinical significance has also
been calculated for EORTC, i.e. a score difference of >10
points. Magnitude of group differences was further ana-
lyzed by means of effect sizes (ES). ES of within-group
change was calculated as mean change between assess-
ments divided by the standard deviation of change [30].
ES were judged against standard criteria proposed by
Cohen: trivial (0 to < 0.2), small (0.2 to < 0.5), moderate
(0.5 to < 0.8) and large (≥ 0.8) [31]. This method supple-
ments usual significance testing and provides standard-
ized effect levels regardless of sample size and scaling
properties.
Ethical aspects
The study was conducted in accordance with the Declara-
tion of Helsinki and was approved by the ethical commit-
tee at Sahlgrenska University Hospital, Göteborg, Sweden.
Results
Socio-demographic characteristics of included and
excluded patients are presented in Table 1. Significant dif-
ferences between included and excluded patients were
found regarding tumour site, stage of disease and WHO
index. The excluded patients more often had a supraglot-
tic tumour, advanced disease and worse performance sta-
tus according to WHO-Index. No significant differences
were found between the included and excluded patients
concerning gender, age, or concurrent diseases.
The questionnaire response rate was 100% at baseline,
95% at one month, 86% at two months, 81% at three
months, 75% at six months and 71% at one year. Of the
71 patients completing the study five were laryngect-
omised while 66 (93%) had preserved larynx. At the end
of the study year five patients still had active disease or
were deceased. Thus, the cumulative response rate of
patients answering all six questionnaires over one year
was 76 %, and the item response rate was 99.5%, i.e., only
0.5% of the questions were left unanswered The 29 drop-
out patients missing at follow-up did not differ from the
participants completing the study regarding gender, age,
civil status or educational level but significantly more
were smokers and had a supraglottic localisation (data
not shown).
Table 1: Clinical characteristics of included and excluded patients
Included (n = 100) Excluded (n = 110) p-value†
Age, median years (range) 67 (27–92) 71 (44–87) ns
Sex ns
Female 17 (17 %) 22 (20 %)
Male 83 (83 %) 88 (80 %)
Tumour site
Glottic 72 (72 %) 61 (55 %) 0.0188
Supraglottic 20 (20 %) 37 (34 %) 0.0382
Subglottic 4 (4 %) 3 (3 %) ns
Transglottic 4 (4 %) 9 (8 %) ns
Stage
0 3 (3 %) 2 (2 %)
I 57 (57 %) 43 (39 %)
II 22 (22 %) 24 (22 %)
III 9 (9 %) 17 (15 %)
IV 9 (9 %) 24 (22 %) 0.0010
Performance status WHO-Index
0 77 (77 %) 62 (59 %)
1 18 (18 %) 25 (24 %)
2 4 (4 %) 13 (12 %)
3 1 (1 %) 4 (4 %)
4 1 (1 %) 0.0016
Married/Cohabitant 70 (70 %) 62 (56 %) ns
Smokers 50 (50 %) 70 (64 %) ns
Loss of weight 21 (21 %) 35 (32 %) ns
Residual disease 2 (2 %) 2 (2 %) ns
Cardiovascular disease 45 (45 %) 38 (35 %) ns
Other malignancy 8 (8 %) 11 (10 %) ns
†p-value significant at ≤ 0.05, ns = not significant
The included patients were classified as N0M0, except one patient classified as N2M0 and two classified as N2M1. In the excluded group 10 patients 
were classified as N1M0, six as N2M0, one as N3M0 and one patient as N2M1.BMC Cancer 2008, 8:80 http://www.biomedcentral.com/1471-2407/8/80
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Questionnaires
S-SECEL
No significant differences in S-SECEL baseline scores were
found between the 29 drop-out patients and the 71
patients completing the study
The mean S-SECEL total and subscale scores at the differ-
ent measurement points are shown in Table 2 and Figure
1. As can be seen, patients report an increase in speech
dysfunction between baseline and one month on all sub-
scales. Changes are statistically significant for the Total,
Attitudinal, and Environmental scales but these changes
are, in ES terms, small (Fig 2). From 2 months throughout
the year there is a continuous decrease in perceived dys-
function on all subscales and the Total scale. Changes
between baseline and 12 months were statistically signifi-
cant for all subscales. ES differences are regarded as mod-
erate for the Total, Environmental and General scales but
only small for the Attitudinal scale (Fig 2).
Two items explained most of the difference in the Envi-
ronmental scale: 'difficulty yelling or calling out to peo-
ple' and 'trouble speaking in large groups' (Mdiff = 0.60/
0.54). These questions also displayed the largest dysfunc-
tion before treatment. For the General scale one item dif-
fered more than the others: 'does your speech improve
with practice' (Mdiff = 0.89) while the smallest change
was noted for 'are you a calm and quiet person'. Items in
the Attitudinal scale scored low both before and after
treatment but the greatest change was found for 'is your
private or social life limited' (Mdiff = 0.37)
EORTC QLQ-C30 and QLQ-H&N35
Data for the EORTC QLQ-C30 and QLQ-H&N35 scales
and items are shown in Table 3 and 4. One month after
treatment start, statistically significant deterioration was
seen in the Role, Social, Emotional and Global QLQ func-
tioning scales, this corresponded to a clinical deteriora-
tion only for Role functioning. Except for Social
functioning, at the 12 month follow-up clinical and/or
statistical significant improvements, compared to base-
line, were reported for all of these scales. For the symptom
scales, an increase in mean scores was seen on all meas-
ures at one month, indicating deterioration. At the last fol-
Mean S-SECEL total and subscale scores Figure 1
Mean S-SECEL total and subscale scores. Shows the mean values over time during the study year for S-SECEL total score 
and subscales. All patients who answered the questionnaires at each measurement point were included in the figure, while the 
p-values refer to Wilcoxon signed rank test in patients with both baseline and follow-up assessments. S-SECEL = Swedish Self 
Evaluation of Communication Experiences after Laryngeal Cancer. env = environmental subscale, gen = general subscale, att = 
attitudinal subscale, tot = total score.
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low-up, however, there were no significant changes
compared to baseline.
For the H&N35, an increase was seen in all scales, but Sex-
uality, as well as all single items at one month, and most
of these were both clinically and statistically significant. At
the 12 month follow-up an improvement compared to
Changes (effects sizes) in S-SECEL and HAD Figure 2
Changes (effects sizes) in S-SECEL and HAD. Changes (effects sizes) in S-SECEL and HAD between (a) baseline and 1 
month follow-up and (b) baseline and 12 month follow-up; neg = negative change, i.e. increased dysfunction and anxiety/depres-
sion.
S-SECEL
a) Baseline vs. 1 mo b) Baseline vs. 12 mo
small trivial moderate large small trivial moderate large
HAD
Dep
Anx
Env
Tot
Gen
Att
Dep
Anx
Env
Tot
Gen
Att
neg
neg
neg
neg
0 0,1 0,2 0,3 0,4 0,5 0,6 0,7 0,8 0,9 1 0 0,1 0,2 0,3 0,4 0,5 0,6 0,7 0,8 0,9 1
Table 2: Mean values (CI) for S-SECEL scores before treatment (baseline) and follow-up and p-values and effect sizes for changes at 
follow-up compared to baseline
Base, n = 100 1 mo, n = 95 2 mo, n = 86 3 mo, n = 81 6 mo, n = 75 12 mo, n = 71
S-SECEL
Total* 25.2 (22.5–28.0) 30.6 (27.3–33.8) 25.6 (21.6–29.6) 20.6 (17.2–24.1) 19.5 (15.3–23.7) 15.4 (11.9–18.9)
p†/ES‡ 0.00/0.34 ns/0.03 0.02/0.24 0.00/0.32 0.00/0.62
Environment* 14.4 (12.8–16.0) 18.1 (16.2–19.9) 14.9 (12.8–17.0) 12.4 (10.4–14.4) 11.0 (8.9–13.1) 8.7 (6.8–10.5)
p†/ES‡ 0.00/0.41 ns/0.04 ns/0.20 0.00/0.35 0.00/0.62
Attitudinal* 5.9 (4.7–7.1) 8.4 (6.6–10.2) 6.7 (5.0–8.4) 4.9 (3.6–6.1) 4.9 (3.0–6.8) 3.7 (2.1–5.3)
p†/ES‡ 0.00/0.29 ns/0.09 ns/0.10 0.50/0.11 0.00/0.32
General* 5.0 (4.5–5.4) 5.2 (4.1–6.2) 4.1 (3.5–4.6) 3.4 (2.9–3.9) 3.6 (3.0–4.1) 3.1 (2.5–3.7)
p†/ES‡ ns/0.05 0.05/0.25 0.00/0.55 0.00/0.53 0.00/0.58
†p-value significant at ≤ 0.05, ns = non significant
*Min-max subscales: 0–15 (general), 0–42 (environmental), 0–45 (attitudinal), and 0–102 (total)
‡Effect size (ES) of change was calculated as mean change from baseline divided by the standard deviation of change. Criteria: trivial 0 to < 0.20; 
small 0.20 to < 0.50; moderate 0.50 to < 0.80; and large ≥ 0.80BMC Cancer 2008, 8:80 http://www.biomedcentral.com/1471-2407/8/80
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baseline was reported for two of the scales and one item.
However, patients still reported more problems with
Senses and Sticky saliva.
HAD
One month after treatment start, patients reported a small
but significant decrease in mean anxiety scores compared
to baseline (Table 5, Fig 2). At the 12 month follow-up
mean values had further decreased, the effect now being
moderate. There were no significant changes for depres-
sion. According to HAD classifications, anxiety was more
prevalent than depression at baseline, 34% vs. 15%. At the
one month and 12 month follow-up 21% vs. 11% of the
patients had possible/probable anxiety disorder. Corre-
sponding figures for possible/probable depression was
21% vs. 8%.
Discussion
Results from our study proved the S-SECEL to be sensitive
to changes in communication and psychosocial dysfunc-
tion longitudinally. The response pattern over time, when
compared to the EORTC QLQ-C30 with H&N35 and the
HAD, lent further support to the construct validity of the
S-SECEL. The response rate for the used set of question-
naires was high, 76% at the last follow-up, supporting the
feasibility of assessment method in clinical settings.
When looking at the individual S-SECEL scales, at the 12-
month follow-up the decrease in the General scale is mod-
erate. However, it should be noted that patients report lit-
tle dysfunction before as well as after treatment. The
General scale displays a somewhat different pattern to the
other subscales during the year. There is no decrease at
one month but already at the two month follow-up a
small but significant improvement is seen. This different
pattern might be explained by items being somewhat dis-
parate, covering questions about voice quality as well as
personality, and therefore of differing relevance. The ques-
tion "Do you think your speech improves with practice"
changes the most over the study period and this is a highly
relevant question since it detects the effect of voice reha-
bilitation measures. It should be noted, that there is no
corresponding question in the EORTC. The question
"Would you describe yourself as a calm and quiet per-
son?" changes the least, probably due to this question
rather measuring a trait of character then effects of illness
or treatment.
Both the Environmental and the Attitudinal subscales
show a small but significant increased dysfunction one
month after start of treatment. This is reasonable since the
patients still receive treatment and therefore are suffering
from various side effects, also affecting the voice. At the
Table 3: Mean values (CI) for EORTC QLQ-C30 scores before treatment (baseline) and follow-up and p-values and effect sizes for 
changes at follow-up compared to baseline
Base, n = 100 1 mo, n = 95 2 mo, n = 86 3 mo, n = 81 6 mo, n = 75 12 mo, n = 71
EORTC QLQ-C30 
Functional scales*
Physical 85.1 (81.5–88.7) 81.7 (78.1–85.3) 81.4 (77.4–85.4) 84.2 (80.5–87.9) 85.6 (81.7–89.5) 88.5 (85.2–91.9)
p†/ES‡ .006/0.32 .001/0.35 .038/0.25 ns/0.18 ns/0.04
Role 77.8 (71.8–83.8) 65.4 § (58.7–72.2) 74.1 (67.3–81.0) 80.7 (74.7–86.6) 85.4 (79.7–91.0) 89.2§ 1 (84.5–93.9)
p†/ES‡ 0.000/0.41 0.011/0.25 ns/0.08 ns/0.06 ns/0.19
Social 86.9 (82.6–91.2) 80.5 (75.7–85.4) 83.5 (78.3–88.8) 87.2 (82.7–91.8) 88.0 (82.5–93.5) 90.1 (85.5–94.8)
p†/ES‡ .005/0.26 ns/0.16 ns/0.09 ns/0.07 ns/0.07
Emotional 74.4 (69.7–79.1) 76.5 (71.9–81.1) 81.7 (77.7–85.6) 84.6§ (80.6–88.6) 83.4 (78.0–88.8) 89.5§ (85.7–93.2)
p†/ES‡ ns/0.09 .042/0.26 .002/0.37 .009/0.33 .000/0.61
Cognitive 83.5 (79.5–87.5) 84.0 (80.3–87.7) 87.8 (84.3–91.3) 88.1 (84.4–91.7) 87.6 (83.7–91.5) 88.3 (84.8–91.7)
p†/ES‡ ns/0.02 ns/0.15 ns/0.16 ns/0.12 ns/0.19
Global QLQ 68.4 (64.1–72.6) 63.5 (59.1–67.9) 69.2 (64.7–73.7) 72.7 (68.4–77.1) 75.1 (69.9–80.3) 77.9 (73.0–82.9)
p†/ES‡ .015/0.24 ns/0.06 ns/0.08 ns/0.13 .007/0.31
Symptom scales*
Pain 17.7 (12.7–22.7) 35.4§ (29.8–41.1) 23.5 (18.0–28.9) 17.7 (12.7–22.7) 14.9 (9.2–20.6) 8.7 (4.7–12.7)
p†/ES‡ .000/0.67 .002/0.35 ns/0.13 ns/0.04 ns/0.04
Fatigue 25.1 (20.6–29.7) 39.3§ (34.1–44.5) 34.6 (29.1–40.2) 30.3 (25.3–35.3) 21.2 (16.3–26.1) 18.2 (13.6–22.7)
p†/ES‡ .000/0.63 .000/0.52 .000/0.41 ns/0.00 ns/0.16
Nausea/vomiting 5.2 (2.9–7.4) 14.2 (9.7–18.8) 12.0 (8.0–16.0) 7.0 (3.2–10.8) 2.7 (1.0–4.3) 1.4 (0.3–2.5)
p†/ES‡ .000/0.40 .000/0.42 ns/0.19 ns/0.05 ns/0.19
*Min-max: 0–100
§ Indicates clinical significant change measured from baseline, i.e. a change of > 10 points
† p-value significant at ≤ 0.05, ns = not significant.
‡ Effect size (ES) of change was calculated as mean change from baseline, divided by the standard deviation of change. Criteria: trivial 0 to < 0.20; 
small 0.20 to < 0.50; moderate 0.50 to < 0.80; and large ≥ 0.80BMC Cancer 2008, 8:80 http://www.biomedcentral.com/1471-2407/8/80
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following measuring points scores decrease, but the
decrease is not significant until the 6 month follow-up
and these results are in accordance with previous studies
[6,17,32]. Although both being significant at the 12
month follow-up the scales differ concerning effects sizes.
As the General scale, the effect in the Environmental scale
is moderate but only small for the Attitudinal. This is
probably explained by the fact that the General and Envi-
ronmental subscales include more voice specific ques-
tions than the Attitudinal, where items are more related to
mental distress and self-esteem.
When reviewing the results of the EORTC QLQ-C30 and
the QLQ-H&N35, we find diverging results for the differ-
ent methods of significance testing. In a number of scales,
at several measurement points, there are statistical but no
clinical significances and effect sizes are small or even triv-
ial. This illustrates the additional value of not using p-val-
ues alone as measure of significance.
Table 4: Mean values (CI) for QLQ-H&N35 scores before treatment (baseline) and follow-up and p-values and effect sizes for changes 
at follow-up compared to baseline
Base, n = 100 1 mo, n = 95 2 mo, n = 86 3 mo, n = 81 6 mo, n = 75 12 mo, n = 71
EORTC QLQ-H&N35
Scales*
Pain 9.3 (6.4–12.2) 28.5§ (23.9–33.0) 17.0 (13.2–20.9) 13.0 (9.2–16.7) 12.3 (7.8–16.7) 6.8 (3.2–10.4)
p†/ES‡ .000/0.99 .000/0.55 .016/0.28 ns/0.21 ns/0.08
Swallowing 6.8 (4.2–9.5) 33.1§ (27.7–38.5) 22.8§ (17.4–28.1) 14.3 (9.1–19.6) 11.3 (6.8–15.7) 6.8 (3.3–10.3)
p†/ES‡ .000/0.96 .000/0.68 .000/0.39 .005/0.34 ns/0.15
Senses 5.2 (2.4–7.9) 23.0§ (17.3–28.6) 19.2§ (13.1–25.3) 13.2 (8.6–17.8) 9.6 (5.0–14.2) 7.8 (3.6–11.9)
p†/ES‡ .000/0.70 .000/0.54 .000/0.49 .005/0.34 .010/0.31
Speech 37.2 (32.5–41.9) 44.9 (39.5–50.4) 34.4 (28.3–40.6) 24.6§ (19.0–30.1) 24.3§ (18.3–30.3) 16.0§ (11.8–20.2)
p†/ES‡ .013/0.25 ns/0.09 .001/0.40 .001/0.45 .000/0.84
Social eating 7.1 (4.1–10.0) 29.1§ (23.3–34.9) 17.4§ (12.6–22.3) 11.0 (6.3–15.7) 7.3 (3.3–11.4) 6.0 (2.1–9.9)
p†/ES‡ .000/0.75 .000/0.50 .014/0.28 ns/0.17 ns/0.09
Social contact 6.9 (4.5–9.3) 9.4 (6.6–12.1) 7.6 (5.2–10.1) 5.2 (2.4–8.1) 4.5 (1.4–7.5) 2.8 (0.3–5.3)
p†/ES‡ .049/0.18 ns/0.10 ns/0.05 ns/0.16 .003/0.36
Sexuality 33.0 (25.4–40.6) 36.6 (28.9–44.3) 37.2 (28.9–45.5) 34.9 (27.1–46.6) 27.1 (19.4–34.9) 27.0 (19.2–34.7)
p†/ES‡ ns/0.12 ns/0.12 ns/0.17 ns/0.05 ns/0.01
Single items*
Dry mouth 22.7 (16.7–28.7) 39.30§ (32.5–46.1) 34.1§ (27.1–41.1) 34.6§ (27.3–41.9) 34.7§ (27.3–42.1) 30.1 (23.4–36.7)
p†/ES‡ .000/0.52 .000/0.44 .000/0.53 .000/0.54 .002/0.40
Sticky saliva 20.2 (14.8–25.6) 50.7§ (43.7–57.7) 45.0§ (37.4–52.5) 37.1§ (29.9–44.3) 38.7§ (30.9–46.4) 31.9§ (25.1–38.7)
p†/ES‡ .000/0.91 .000/0.80 .000/0.68 .000/0.66 .000/0.55
Coughing 29.0 (24.0–34.0) 48.1§ (42.0–54.2) 40.3§ (33.5–47.1) 35.4 (29.2–41.6) 32.4 (25.0–39.9) 24.9 (18.8–31.0)
p†/ES‡ .000/0.63 .004/0.33 .026/0.26 ns/0.21 ns/0.02
Felt ill 17.0 (12.4–21.6) 28.4§ (22.4–34.4) 19.0 (13.7–24.3) 16.1 (11.1–21.1) 10.2 (6.2–14.2) 8.5 (4.5–12.4)
p†/ES‡ .000/0.0.45 ns/0.17 ns/0.08 ns/0.20 .034/0.26
*Min-max: 0–100
§ Indicates clinical significant change measured from baseline, i.e. a change of >10 points.
†p-value significant at ≤ 0.05, ns = not significant.
‡Effect size (ES) of change was calculated as mean change from baseline, divided by the standard deviation of change. Criteria: trivial 0 to < 0.20; 
small 0.20 to < 0.50; moderate 0.50 to < 0.80; and large ≥ 0.80
Table 5: Mean values (CI) for HAD scores before treatment (baseline) and follow-up and p-values and effect sizes for changes at follow-
up compared to baseline
HAD Base, n = 100 1 mo, n = 95 2 mo, n = 86 3 mo, n = 81 6 mo, n = 75 12 mo, n = 71
Anxiety* 5.4 (4.5–6.3) 4.1 (3.2–5.0) 3.1 (2.4–3.8) 4.5 (2.8–4.3) 3.4 (2.5–4.4) 3.2 (2.2–4.1)
p†/ES‡ 0.00/0.31 0.00/0.50 0.00/0.37 0.00/0.41 0.00/0.51
Depression* 3.7 (3.0–4.5) 4.0 (3.2–4.8) 3.2 (2.6–3.8) 2.9 (2.3–3.5) 2.8 (2.0–3.6) 2.5 (1.7–3.3)
p†/ES‡ ns/0.12 ns/0.03 ns/0.08 ns/0.07 ns/0.20
*Min-max score 0–21
†p-value significant at ≤ 0.05, ns = not significant
‡Effect size (ES) of change was calculated as mean change from baseline, divided by the standard deviation of change. Criteria: trivial 0 to < 0.20; 
small 0.20 to < 0.50; moderate 0.50 to < 0.80; and large ≥ 0.80BMC Cancer 2008, 8:80 http://www.biomedcentral.com/1471-2407/8/80
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In the EORTC QLQ-C30, only two of the scales, Role and
Emotional, show significant changes at 12 months. The
questions that constitute these scales have their equiva-
lence in the S-SECEL. The Role scale consists of two ques-
tions concerning how the disease affects patients' ability
to function in daily activities, work and leisure. This area
is more specifically covered in the subscale Environmental
of the S-SECEL. The Emotional scale in the EORTC con-
sists of four questions about feeling annoyed, depressed,
tense or worried. Some of these symptoms are covered in
the Attitudinal scale and there in relation to voice and
speech. This is an important distinction since, for exam-
ple, one can feel annoyed in a specific situation such as a
conversation without feel annoyed in general.
The significant changes in C30 and H&N35, statistically as
well as clinically, are mainly seen in items in the head and
neck module. All single items show significant changes
one month after start of treatment as well as four of the
scales. As with the S-SECEL, these changes probably reflect
treatment effects. At one year there is only one clinically
significant improvement reported, the Speech scale. It is
well known that the main problems for patients with
laryngeal cancer are voice related. The Speech scale in the
QLQ-H&N35, however, consists of only two questions
directly addressing quality of voice and speech; "Difficul-
ties speaking to other people?" and "Problems speaking
on the phone?". The scales Senses and Social contact and
the single item Dry mouth show statistical significance at
12 months, but the effect sizes were only small and not
clinically significant. Müller et al [13] argue that the QLQ-
H&N35 are not specific enough and stress that question-
naires should be more precise when used on patients with
laryngeal cancer. Op de Coul et al [12] have also under-
lined the necessity to develop and use more specific addi-
tional questionnaires as an adjunct to the existing EORTC
questionnaires when studying specific symptoms in laryn-
gectomised patients. In the SECEL items are more
detailed, e.g. questions about speaking to others specify if
it concerns speaking in large or small groups or to an indi-
vidual.
Baseline results of the HAD scale corresponds well to
other comparable studies [16,33], both regarding Anxiety
and Depression. The decrease in Anxiety reported at the
one month follow-up may seem contradictory to the
increased dysfunction according to the S-SECEL. How-
ever, this could be due to a feeling of relief having been
diagnosed and receiving treatment. This improvement,
however, was not found in the Emotional scale of the
EORTC QLQ-C30. Singer et al [34] found that the HAD
scale showed a higher rate of accuracy than the EORTC's
Emotional scale when measuring psychiatric morbidity in
laryngeal cancer patients, which might explain this dis-
crepancy. At the 12 month follow-up mean values for
Anxiety had further decreased, the improvement in men-
tal health now also being reflected in the Emotional scale.
Mean values of depression was low at baseline and did
not change, a finding in line with previous studies, e.g.
[33]. However, the prevalence of patients with possible/
probable depression increased after treatment start and
this might be due to the increase in dysfunction following
treatment. After one year, and terminated treatment, the
prevalence was lower than at baseline. We have used the
recommended cut off values for possible and probable
Depression and Anxiety; however it has been discussed
whether there is a need for different cut off values for dif-
ferent populations [34,35]. For example, Zöger et al used
the HAD when screening for anxiety and depression in
patients with tinnitus, and found optimal cut-off score for
these patients to be ≥ 5 [36].
A shortcoming of our study is that the patients excluded
from the study had a more advanced disease and lower
performance status than those included. This might have
lead to an underestimation of the prevalence of psychiat-
ric morbidity and communication dysfunction. On the
other hand, this is to our knowledge the largest Scandina-
vian longitudinal study made on HRQL and communica-
tion dysfunction in patients treated for laryngeal cancer.
Conclusion
The S-SECEL has been investigated in the largest Scandi-
navian longitudinal study concerning HRQL in patients
with laryngeal cancer. The questionnaire is sensitive to
change over time and shows convergent results when
compared to established HRQL questionnaires. Our find-
ings also indicate that the S-SECEL could be a more suita-
ble instrument than the EORTC QLQ-C30 with QLQ-
H&N35 in patients with laryngeal cancer; it is more sensi-
tive, it is shorter and can be used on an individual basis.
As a routine screening instrument, with the use of a spe-
cific cut off value, the S-SECEL could be a valuable tool for
identifying patients at risk for psychosocial problems, to
help to plan rehabilitation. It is therefore recommended
for clinical use in evaluation of communication dysfunc-
tion for all patients with laryngeal cancer irrespective of
treatment.
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Appendix
General scale
1) feel relaxed and comfortable in social settings
2) describe yourself as calm and quiet
3) describe yourself as outgoing, talkative
4) admit having had laryngeal cancer
5) your speech improves with practice
Environmental scale
1) limited in meetings due to speech
2) difficulty getting peoples' attention
3) difficulty yelling or calling out to people
4) people having difficulty to understand
5) repeat things to be understood
6) trouble speaking in large groups
7) trouble speaking in small groups
8) trouble speaking with one person
9) trouble speaking in different rooms
10) trouble speaking in loud and noisy places
11) trouble speaking on telephone
12) trouble speaking in car or bus
13) difficulty attending parties or social activities
14) use telephone less often
Attitudinal scale
1) feel left out in group
2) limited private or social life
3) depressed due to speech
4) frustrated when not understood
5) different or peculiar
6) hesitate to meet new people
7) get left out of conversations
8) avoid speaking
9) people fill in words
10) people interrupt
11) people tell you they can't understand
12) people get annoyed
13) people avoid you
14) people speak differently to you
15) family and friends difficulty understanding your com-
munication situation
Response alternatives: Always/Most of the time/Some-
times/Never
Single item
1) Do you talk the same amount now as before your laryn-
geal cancer?
Response alternatives: Yes/More/Less
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